Global Cancer Consortium: Cardio-Oncology Series - Shared screen with speaker view
Who can see your viewing activity?
Please post any questions in the chat and we will go over them at the end of the talk. Thank you. Amit Arbune
Could you comment on the role of metformin in cardio-protection that goes beyond its hypoglycemic effects.
Is cardiotoxicity in cancers may be due to drug interactions between cardiovascular drugs with anticancer drugs or immunotherapy drugs? Do you think pharmacogenomics screening for drug metabolizing enzymes before cancer therapy for these drugs may be helpful.?
how to monitor patients on immunotherapy for cardiac toxicity? like we monitor cardiac LV function for patients on anthracyclines or anti her 2 therapy which can cause LV dysfunction. are there any known biomarkers?
Is medical cardioprotection warranted for cardiotoxicity due to radiation?
whether statins act as a risk factor in prostate/skin cancer?
do you have any recommendations about risk assessment tools for use by oncology to help identify patients who may be at higher risk of cardiotoxicity?
https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1920 - baseline CV risk assessment in pts scheduled to receive cardiotoxic therapies